Hematologic Malignancies
6.0
credits/contact hours

Learn From the Experts About Collaborative Practice in the Management of Cancer Patients

Gain insights and clinical knowledge on the science of new targeted therapies and immunotherapies for the treatment of hematologic malignancies. Learn how to manage the side effects and other clinical issues associated with these new treatments in a case-based, informal educational setting. 



Boston, MA • October 7

Venue to be announced soon!Register Now

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

  • Identify the mechanism of action for novel agents used for the treatment of hematological malignancies including Multiple Myeloma, CLL, Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL).
  • List monitoring parameters for toxicities associated with newer agents used to treat multiple myeloma, CLL, HL, and NHL.
  • Describe the signs of early and serious toxicity that providers and patients need to be aware of when initiating therapy with new agents for multiple myeloma, CLL, HL and NHL.
  • Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings.
  • Anticipate and identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome.
  • Identify strategies for encouraging patient adherence to oral therapeutics.
  • Discuss the pivotal role and necessary expertise of the AP as a vital part of the inter-professional oncology/hematology team.

 

REGISTRATION FEE

  Member Non-Member
Registration $25.00 $50.00

AGENDA

7:30 am Registration
8:00 am Breakfast
9:00 am Welcome and Introductions
9:15 am Updates In Multiple Myeloma Risk Stratification – 1.25 Contact Hours
  • Risk Stratification
  • MOA – IMIDs/ Proteasome Inhibitors/ Immunotherapy
  • Emerging Therapies
  • Management of Adverse Events
  • Case Study
10:30 am Break
10:45 am Updates In Chronic Lymphocytic Leukemia – 1.25 Contact Hours
  • Risk Stratification
  • Monoclonal antibodies
  • B-cell Receptors
  • Emerging Therapies
  • Management of Adverse Events
  • Case Study
12:00 pm Lunch Break
1:15 pm Updates In Hodgkin Lymphoma – 1.25 Contact Hours
  • Risk Stratification
  • Monoclonal antibodies
  • Antibody Drug Conjugates
  • Immunotherapy
  • Management of Adverse Events
  • Case Study
2:30 pm Break
2.40 pm iPad drawing
2:45 pm Updates In Non-Hodgkin Lymphoma – 1.25 Contact Hours
  • Risk Stratification
  • Monoclonal antibodies
  • Immunotherapy
  • Management of Adverse Events
  • Case Study
4:00 pm Strategies for Adherence to Oral Therapeutics – 0.75 Contact Hours
4:45 pm Reflections on the day – 0.25 Contact Hours
5:00 pm Program adjourns

*Program times are subject to change.

Boston, MA • October 7

Venue to be announced soon!Register Now

ACCREDITATION


Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 6.0 contact hours may be earned for successful completion of this activity.

Pharmacists: The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program 0797-9999-17-031-L01-P.

This program is designated for up to 6.0 contact hours (0.600 CEUs) of continuing pharmacy education credit.

PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

PAs may receive a maximum of 6.0 Category 1 credits for completing this activity.

Support provided by educational grants from Celgene Corporation and Amgen.

This CE/CME/CEU accredited conference is jointly provided by